Invivyd Inc (IVVD)
1.84
+0.03
(+1.66%)
USD |
NASDAQ |
May 31, 16:00
1.83
-0.01
(-0.54%)
After-Hours: 20:00
Invivyd Research and Development Expense (Annual): 158.66M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 158.66M |
| December 31, 2022 | 179.21M |
| Date | Value |
|---|---|
| December 31, 2021 | 182.89M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
158.66M
Minimum
2023
182.89M
Maximum
2021
173.59M
Average
179.21M
Median
2022
Research and Development Expense (Annual) Benchmarks
| Vanda Pharmaceuticals Inc | 76.82M |
| Viking Therapeutics Inc | 63.81M |
| Stoke Therapeutics Inc | 82.23M |
| 180 Life Sciences Corp | 2.784M |
| MAIA Biotechnology Inc | 11.11M |